tetano
Editor, Senior Moderator
Medicine (Baltimore)
. 2022 May 6;101(18):e29027.
doi: 10.1097/MD.0000000000029027.
The effect of Epstein-Barr virus viremia on the progression to severe COVID-19
Jae Hyoung Im[SUP] 1 [/SUP], Chung Hyun Nahm[SUP] 2 [/SUP], Young Soo Je[SUP] 3 [/SUP], Jin-Soo Lee[SUP] 1 [/SUP], Ji Hyeon Baek[SUP] 1 [/SUP], Hea Yoon Kwon[SUP] 1 [/SUP], Moon-Hyun Chung[SUP] 4 [/SUP], Ji-Hun Jang[SUP] 5 [/SUP], Jung Soo Kim[SUP] 6 [/SUP], Jun Hyeok Lim[SUP] 7 [/SUP], Mi Hwa Park[SUP] 7 [/SUP]
Affiliations
Abstract
Epstein-Barr virus (EBV) is frequently reactivated by coronavirus 2019 (COVID-19), and a high incidence of EBV viremia has been reported in patients with severe COVID-19. However, the impact of EBV viremia on progression to severe COVID-19 is unclear. Therefore, we conducted a study to evaluate the effect of EBV on COVID-19 progression.We investigated EBV viremia at the time of admission in COVID-19 patients hospitalized between February 1, 2020, and April 11, 2021. A cross-sectional study was performed to compare the severity of COVID-19 according to the presence or absence of EBV viremia. However, since it is difficult to analyze the influence of EBV viremia on COVID-19 progression with cross-sectional studies, a retrospective cohort study, limited to patients with mild COVID-19, was additionally conducted to observe progression to severe COVID-19 according to the presence or absence of EBV viremia.Two hundred sixty-nine COVID-19 patients were tested for EBV viremia. In a cross-sectional study that included patients with both mild and severe COVID-19, the EBV viremia group had more severe pneumonia than the EBV-negative group. However, in the cohort study limited to mild cases (N = 213), EBV viremia was not associated with COVID-19 progression.COVID-19 severity may affect EBV viremia; however, there was no evidence that EBV viremia was a factor in exacerbating pneumonia in patients with mild COVID-19.
. 2022 May 6;101(18):e29027.
doi: 10.1097/MD.0000000000029027.
The effect of Epstein-Barr virus viremia on the progression to severe COVID-19
Jae Hyoung Im[SUP] 1 [/SUP], Chung Hyun Nahm[SUP] 2 [/SUP], Young Soo Je[SUP] 3 [/SUP], Jin-Soo Lee[SUP] 1 [/SUP], Ji Hyeon Baek[SUP] 1 [/SUP], Hea Yoon Kwon[SUP] 1 [/SUP], Moon-Hyun Chung[SUP] 4 [/SUP], Ji-Hun Jang[SUP] 5 [/SUP], Jung Soo Kim[SUP] 6 [/SUP], Jun Hyeok Lim[SUP] 7 [/SUP], Mi Hwa Park[SUP] 7 [/SUP]
Affiliations
- PMID: 35550458
- DOI: 10.1097/MD.0000000000029027
Abstract
Epstein-Barr virus (EBV) is frequently reactivated by coronavirus 2019 (COVID-19), and a high incidence of EBV viremia has been reported in patients with severe COVID-19. However, the impact of EBV viremia on progression to severe COVID-19 is unclear. Therefore, we conducted a study to evaluate the effect of EBV on COVID-19 progression.We investigated EBV viremia at the time of admission in COVID-19 patients hospitalized between February 1, 2020, and April 11, 2021. A cross-sectional study was performed to compare the severity of COVID-19 according to the presence or absence of EBV viremia. However, since it is difficult to analyze the influence of EBV viremia on COVID-19 progression with cross-sectional studies, a retrospective cohort study, limited to patients with mild COVID-19, was additionally conducted to observe progression to severe COVID-19 according to the presence or absence of EBV viremia.Two hundred sixty-nine COVID-19 patients were tested for EBV viremia. In a cross-sectional study that included patients with both mild and severe COVID-19, the EBV viremia group had more severe pneumonia than the EBV-negative group. However, in the cohort study limited to mild cases (N = 213), EBV viremia was not associated with COVID-19 progression.COVID-19 severity may affect EBV viremia; however, there was no evidence that EBV viremia was a factor in exacerbating pneumonia in patients with mild COVID-19.